Pharmacophore modeling for COX-1 and-2 inhibitors with LigandScout in comparison to Discovery Studio

Future Medicinal Chemistry

Volumn 6, Issue 17, 2014, Pages 1869-1881

  Temml, Veronika ^a   Kaserer, Teresa ^a   Kutil, Zsofia ^b,c   Landa, Premysl ^b   Vanek, Tomas ^b   Schuster, Daniela ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

^c CZECH UNIVERSITY OF LIFE SCIENCES PRAGUE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LIGAND; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BINDING;

CELL FREE SYSTEM; COMPARATIVE STUDY; COMPUTER AIDED DESIGN; COMPUTER MODEL; COMPUTER PROGRAM; DRUG SCREENING; ENZYME ASSAY; PHARMACOPHORE; REVIEW; BINDING SITE; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM; MOLECULAR DOCKING; PROTEIN TERTIARY STRUCTURE;

BINDING SITES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 84919789130     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.114     Document Type: Review

References (50)

1. Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. Pharmacol. Rev. 66(1), 334-395 (2014
2. Wermuth G, Ganellin CR, Lindberg P, Mitscher LA. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998). Pure Appl. Chem. 70(5), 1129-1143 (1998
3. Hein M, Zilian D, Sotriffer CA. Docking compared to 3D-pharmacophores: The scoring function challenge. Drug Discov. Today Technol. 7(4), E229-E236 (2010
4. Guner O, Clement O, Kurogi Y. Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. Curr. Med. Chem. 11(22), 2991-3005 (2004
5. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 45(1), 160-169 (2005
6. Labute P, Williams C, Feher M, Sourial E, Schmidt JM. Flexible alignment of small molecules. J. Med. Chem. 44(10), 1483-1490 (2001
7. Moro S, Braiuca P, Deflorian F et al. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo [4, 3-e]1, 2, 4-triazolo[1, 5-c] pyrimidine derivatives as a key study. J. Med. Chem. 48(1), 152-162 (2004
8. Schuster D, Waltenberger B, Kirchmair J et al. Predicting cyclooxygenase inhibition by three-dimensional pharmacophoric profiling. Part I: model generation, validation and applicability in ethnopharmacology. Mol. Inf. 29(1-2), 75-86 (2010
9. Spitzer GM, Heiss M, Mangold M et al. One concept, three implementations of 3D pharmacophore-based virtual screening: distinct coverage of chemical search space. J. Chem. Inf. Model. 50(7), 1241-1247 (2010
10. Sanders MPA, Barbosa AJM, Zarzycka B et al. Comparative analysis of pharmacophore screening tools. J. Chem. Inf. Model. 52(6), 1607-1620 (2012
11. Schuster D, Laggner C, Steindl TM, Langer T. Development and validation of an in silico P450 profiler based on pharmacophore models. Curr. Drug Discov. Technol. 3(1), 1-48 (2006
12. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J. Lipid Res. 50, S29-S34 (2009
13. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol. 3(11), 927-933 (1996
14. Al-Hourani BJ, Sharma SK, Suresh M, Wuest F. Cyclooxygenase-2 inhibitors: a literature and patent review (2009-2010). Expert Opin. Ther. Pat. 21(9), 1339-1432 (2011
15. Vitale P, Perrone MG, Malerba P, Lavecchia A, Scilimati A. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles. Eur. J. Med. Chem. 74(0), 606-618 (2014
16. Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J. Pharm. Res. 10(4), 655-683 (2011
17. Vuorinen A, Nashev LG, Odermatt A, Rollinger JM, Schuster D. Pharmacophore model refinement for 11?-hydroxysteroid dehydrogenase inhibitors: search for modulators of intracellular glucocorticoid concentrations. Mol. Inf. 33(1), 15-25 (2014
18. Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of Useful Decoys, Enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55(14), 6582-6594 (2012
19. Huang N, Shoichet BK, Irwin JJ. Benchmarking sets for molecular docking. J. Med. Chem. 49(23), 6789-6801 (2006
20. Gaulton A, Bellis LJ, Bento AP et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40(D1), D1100-D1107 (2012
21. Loll PJ, Picot D, Ekabo O, Garavito RM. Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H-2 synthase cyclooxygenase active site. Biochemistry 35(23), 7330-7340 (1996
22. Gupta K, Selinsky BS, Kaub CJ, Katz AK, Loll PJ. The 2.0 A resolution crystal structure of prostaglandin H-2 synthase-1: structural insights into an unusual peroxidase. J. Mol. Biol. 335(2), 503-518 (2004
23. Gupta K, Selinsky BS, Loll PJ. 2.0 angstrom structure of prostaglandin H-2 synthase-1 reconstituted with a manganese porphyrin cofactor. Acta Crystallogr. D62, 151-156 (2006
24. Kurumbail RG, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature 384(6610), 644-648 (1996
25. Wang JL, Limburg D, Graneto MJ et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life. Bioorg. Med. Chem. Lett. 20(23), 7159-7163 (2010
26. Duggan KC, Walters MJ, Musee J et al. Molecular basis for cyclooxygenase inhibition by the non-steroidal antiinflammatory drug naproxen. J. Biol. Chem. 285(45), 34950-34959 (2010
27. Smith WL, Dewitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182 (2000
28. Malkowski MG, Ginell SL, Smith WL, Garavito RM. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 289(5486), 1933-1937 (2000
29. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 50(7), 1425-1441 (2007
30. Reininger EA, Bauer R. Prostaglandin-H-synthase (PGHS)-1 and-2 microtiter assays for the testing of herbal drugs and in vitro inhibition of PGHS-isoenzyms by polyunsaturated fatty acids from Platycodi radix. Phytomedicine 13(3), 164-169 (2006
31. OMEGA version 2.3.3. http://www.eyesopen.com. OpenEye Scientific Software, Santa Fe, NM, Hawkins PCD, Skillman AG, Warren GL, Ellingson BA, Stahl MT. Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database. J. Chem. Inf. Model. 50(4), 572-584 (2010
32. Halgren TA. Merck molecular force field.1. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 17(5-6), 490-519 (1996
33. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM - a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4(2), 187-217 (1983
34. Lifson S, Warshel A. Consistent force field for calculations of conformations of conformations vibrational spectra and enthalpies of cycloalkane and n-alkane molecules. J. Chem. Phys. 49(11), 5116 (1968
35. Smellie A, Teig SL, Towbin P. Poling - promoting conformational variation. J. Comput. Chem. 16(2), 171-187 (1995
36. Varma-O'Brien SST. Finding 'Bioactive' Conformations using Catalyst's Conformer Generation Algorithm. Catalyst Application Note. http://accelrys.com/resource-center/case-studies/archive/studies/catalyst-conformers-0805.pdf 37 Li J, Ehlers T, Sutter J, Varma-O'brien S, Kirchmair J. CAESAR: A new conformer generation algorithm based on recursive buildup and local rotational symmetry consideration. J. Chem. Inf. Model. 47(5), 1923-1932 (2007
37. Bohm HJ. The computer program LUDI - a new method for the denovo design of enzyme inhibitors. J. Comput. Aid. Mol. Des. 6(1), 61-78 (1992
38. Wolber G, Seidel T, Bendix F, Langer T. Moleculepharmacophore superpositioning and pattern matching in computational drug design. Drug Discov. Today 13(1-2), 23-29 (2008
39. Kabsch W. A solution for the best rotation to relate two sets of vectors. Acta Cryst. A32, 922 (1976
40. Wolber G, Dornhofer AA, Langer T. Efficient overlay of small organic molecules using 3D pharmacophores. J. Comput. Aid. Mol. Des. 20(12), 773-788 (2006
41. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 50(7), 1425-1441 (2007
42. Sidhu RS, Lee JY, Yuan C, Smith WL. Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry 49(33), 7069-7079 (2010
43. Limongelli V, Bonomi M, Marinelli L et al. Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition. Proc. Natl Acad. Sci. USA 107(12), 5411-5416 (2010
44. BioVia, Discovery Studio Vers. 2.5, San Diego, CA, USA. (2011
45. Goodsell DS, Olson AJ. Automated docking of substrates to proteins by simulated annealing. Proteins 8(3), 195-202 (1990
46. Pipeline Pilot, Vers. 6.0, Accelrys Inc., San Diego, CA, USA (2011
47. Warr WA. Scientific workflow systems: Pipeline Pilot and KNIME. J. Comput. Aid. Mol. Des. 26(7), 801-804 (2012
48. Kirchmair J, Wolber G, Laggner C, Langer T. Comparative performance assessment of the conformational model generators omega and catalyst: a large-scale survey on the retrieval of protein-bound ligand conformations. J. Chem. Inf. Model. 46(4), 1848-1861 (2006
49. Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nat. Struct. Biol. 10(12), 980-980 (2003
50. Specs. www.specs.net 52 Maybridge. www.maybridge.com 53 VitasM. www.vitasmlab.com 54 DNTI project. www.uibk.ac.at/pharmazie/pharmakognosie/dnti